What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (NMOSD) Contact Protocol code: ALXN1210-NMO-307 EudraCT code: 2019-003352-37 Pathology: Malalties del sistema nerviós Principal investigator: Montalban Gairín, Xavier Research group: Neuroimmunologia clínica Service: Neuroimmunologia Phase: Fase III Recruiting: Open Status: Iniciat Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARAEVALUAR LA EFICACIA Y LA SEGURIDAD DE OBINUTUZUMAB EN PACIENTES CON NEFRITIS LÚPICADE CLASE III O IV DE LA ISN/RPS DE 2003 Contact Protocol code: CA41705 EudraCT code: 2019-004034-42 Pathology: Malalties de la sang i dels òrgans hematopoètics i certs trastorns que afecten el mecanisme de la immunitat Principal investigator: Cortes Hernandez, Josefina Research group: Reumatologia Service: Reumatologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de seltorexant 20 mg como tratamiento complementario a los antidepresivos en pacientes adultos y de edad avanzada con trastorno depresivo mayor con síntomas de insomnio que respondieron de manera inadecuada al tratamiento con antidepresivos y un tratamiento de extensión de seguridad abierto a largo plazo con seltorexant Contact Protocol code: 42847922MDD3001 EudraCT code: 2020-000337-40 Pathology: Trastorns mentals i del comportament Principal investigator: Vendrell Serres, Julia Research group: Psiquiatria, salut mental i addiccions Service: Psiquiatria Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase II, aleatorizado, no comparativo y abierto de atezolizumab más bevacizumab, con carboplatino-paclitaxel o pemetrexed, en carcinoma de pulmón no microcítico con mutación de EGFR y resistencia adquirida Contact Protocol code: ETOP 15-19 EudraCT code: 2019-001687-30 Pathology: Tumors Principal investigator: Gonzalez Callejo, Patricia Service: Sense classificar Phase: Fase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. HELIOS-B: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de vutrisirán en pacientes con amiloidosis cardiaca por transtiretina (amiloidosis por ATTR con miocardiopatía). Contact Protocol code: ALN-TTRSC02-003 EudraCT code: 2019-003153-28 Pathology: Malalties del sistema circulatori Principal investigator: Martínez Valle, Fernando Research group: Malalties sistèmiques Service: Medicina Interna Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio para evaluar la eficacia, la seguridad y la farmacocinética de IgPro20 (inmunoglobulina subcutánea, Hizentra®) en adultos con dermatomiositis (DM) – Estudio RECLAIIM Contact Protocol code: IgPro20_3007 EudraCT code: 2018-003171-35 Pathology: Nervous system diseases Principal investigator: Juntas Morales, Raul Research group: Sistema nerviós perifèric Service: Neurologia Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de seguridad posautorización para evaluar la seguridad y la eficacia a largo plazo de la administración repetida de darvadstrocel en pacientes con enfermedad de Crohn y fístulas perianales complejas (ASPIRE) Contact Protocol code: Alofisel-4001 EudraCT code: 2017-002491-10 Principal investigator: Casellas Jordá, Francesc Research group: Fisiologia i fisiopatologia digestiva Service: Digestiu Phase: Fase IV Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de pimavanserina como tratamiento complementario para los síntomas negativos de la esquizofrenia (Advance-2) Contact Protocol code: ACP-103-064 EudraCT code: 2019-003343-29 Pathology: Nervous system diseases Principal investigator: Ramos Quiroga, José Antonio Research group: Psychiatry, Mental Health and Addictions Service: Psychiatry Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de Ad26.COV2.S para la prevención de COVID-19 mediada por SARS-CoV-2 en Adultos mayores de 18 años. Contact Protocol code: VAC31518COV3009 EudraCT code: 2020-003643-29 Pathology: Certes malalties infeccioses i parasitàries Principal investigator: Otero Romero, Susana Research group: Epidemologia i salut pública Service: Medicina Preventiva Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo de prueba de concepto y determinación de la dosis en fase II, aleatorizado, controlado con placebo y con doble enmascaramiento para investigar la eficacia y la seguridad de runcaciguat (BAY 1101042) en pacientes con retinopatía diabética no proliferativa de moderadamente severa a severa. NEON-NPDR Contact Protocol code: 20739 EudraCT code: 2020-002333-15 Pathology: Malalties de l’ull i dels seus annexos Principal investigator: Boixadera Espax, Ana Research group: Oftalmologia Service: Oftalmologia Phase: Phase II Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. El efecto del dupilumab en la función pulmonar y los cambios relacionados en los volúmenes de las vías respiratorias detectables mediante imágenes respiratorias funcionales en pacientes con asma moderada-severa.VESTIGE Contact Protocol code: LPS15834 EudraCT code: 2019-004647-74 Pathology: Malalties del sistema respiratori Principal investigator: Muñoz Gall, Fco. Javier Research group: Pneumologia Service: Pneumologia Phase: Phase IV Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo clínico de fase III, multicéntrico, abierto y de ampliación para demostrar la eficacia y la seguridad de Ciclosporina A Liposómica (L-CsA) solución para inhalación administrada mediante el dispositivo en investigación eFlow® de PARI más el tratamiento de referencia en el tratamiento del síndrome de bronquiolitis obliterante en pacientes tras un trasplante pulmonar simple o doble Contact Protocol code: BT–L-CsA–303–FU EudraCT code: 2019-002987-29 Pathology: Diseases of the respiratory system Principal investigator: Monforte Torres, Victor Research group: Pneumology Service: Pneumology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Un estudio de fase 3, aleatorizado, doble ciego, controlado con placebo de atrasentan en pacientes con nefropatía por IgA con riesgo de pérdida progresiva de la función renal (el estudio ALIGN). Contact Protocol code: CHK01-01 EudraCT code: 2020-003084-26 Pathology: Malalties del sistema genitourinari Principal investigator: Agraz Pamplona, Irene Research group: Nefrologia i trasplantament renal Service: Nefrologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3 multicéntrico, doble ciego, aleatorizado, controlado con placebo y de grupos paralelos, seguido de una fase de tratamiento activo para evaluar la eficacia y seguridad de apremilast en niños de 2 a menos de 18 años con úlceras bucales activas asociadas a la enfermedad de Behçet (BEAN). Contact Protocol code: 20190530 EudraCT code: 2019-002787-27 Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Principal investigator: Lopez Corbeto, Mireia Research group: Rheumatology Service: Rheumatology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de prueba de concepto, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de Elezanumab en ictus isquémico agudo. (EAISE) Contact Protocol code: M19-148 EudraCT code: 2019-003753-29 Principal investigator: Molina Cateriano, Carlos Research group: Recerca en ictus Service: Neurology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de prueba de concepto, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia del Elezanumab en la lesión aguda traumática de médula espinal cervical. (ELASCI) Contact Protocol code: M16-077 EudraCT code: 2019-003752-36 Pathology: Malalties del sistema osteomuscular i del teixit connectiu Principal investigator: Sánchez Raya, Judith Research group: Grup de recerca medicina física i rehabilitació Service: Rehabilitació Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase IIb, multicéntrico, aleatorizado, con doble enmascaramiento y comparativo con placebo, para evaluar la eficacia y la seguridad de un único implante de osteoblastos alogénicos (ALLOB®) en la fractura de tibia Contact Protocol code: 000013/BT EudraCT code: 2018-001054-96 Pathology: Factors que influencien en l’estat de salut i contacte amb els serveis de salut Principal investigator: Selga Marsà, Jordi Research group: Cirurgia reconstructiva de l'aparell locomotor Service: Cirurgia Traumatològica Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia analgésica y la seguridad de una combinación en dosis fijas por vía oral de dexketoprofeno trometamol y tramadol hidrocloruro en el dolor agudo de moderado a intenso en pacientes con lumbalgia aguda: estudio DANTE Contact Protocol code: MEIN/18/DEX-LBP/001 EudraCT code: 2019-003656-37 Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Medel Rebollo, Francisco Javier Research group: Farmacologia clínica Service: Anestèsia Phase: Phase IV Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity Followed by an Open-label Extension Period. Contact Protocol code: D-FR-10200-001 EudraCT code: 2020-003623-42 Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Rodriguez Gonzalez, Susana Research group: Research Group of Physical Medicine and Rehabilitation Service: Rehabilitation Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de tratamiento y de 3 brazos grupos paralelos para investigar la eficacia, la seguridad y la tolerabilidad de ro7017773 en participantes de 15 a 45 años de edad con trastorno del espectro autista (tea). Contact Protocol code: BP41316 EudraCT code: 2019-003524-20 Pathology: Mental and behavioral disorders Principal investigator: Gisbert Gustemps, Laura Research group: Psychiatry, Mental Health and Addictions Service: Psychiatry Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Pagination First page « Previous page ‹ … Page 1545 Page 1546 Current page 1547 Page 1548 Page 1549 … Next page › Last page »
